Abstract
Background and Objectives
Curcumin is the major bioactive component of turmeric, but has poor oral bioavailability that limits its clinical applications. To improve the in vitro solubility and alkaline stability, we developed a prodrug of curcumin by succinylation to obtain curcumin diethyl disuccinate, with the goal of improving the oral bioavailability of curcumin.
Methods
The in vivo pharmacokinetic profile of curcumin diethyl disuccinate was compared with that of curcumin in male Wistar rats. Doses of curcumin 20 mg/kg intravenous or 40 mg/kg oral were used as standard regimens for comparison with the prodrug at equivalent doses in healthy adult rats. Blood, tissues, urine, and faeces were collected from time zero to 48 h after dosing to determine the prodrug level, curcumin level and a major metabolite by liquid chromatography-tandem spectrometry.
Results
The absolute oral bioavailability of curcumin diethyl disuccinate was not significantly improved compared with curcumin, with both compounds having oral bioavailability of curcumin less than 1 %. The major metabolic pathway of the prodrug was rapid hydrolysis to obtain curcumin, followed by glucuronidation. Interestingly, curcumin diethyl disuccinate gave superior tissue distribution with higher tissue to plasma ratio of curcumin and curcumin glucuronide in several organs after intravenous dosing at 1 and 4 h. The primary elimination route of curcumin glucuronide occurred via biliary and faecal excretion, with evidence of an entry into the enterohepatic circulation.
Conclusion
Curcumin diethyl disuccinate did not significantly improve the oral bioavailability of curcumin due to first pass metabolism in the gastrointestinal tract. Further studies on reduction of first pass metabolism are required to optimise delivery of curcumin using a prodrug approach.
Similar content being viewed by others
References
Howe E, Keiwkarnka B, Khan MI. Traditional medicine and medicinal plants: utilization, policy and research in Thailand. J Public Health. 2004;2:102.
Satyapan N, Patarakitvanit S, Temboonkiet S, Vudhironarit T, Tankanitlert J. Herbal medicine: affecting factors and prevalence of use among Thai population in Bangkok. J Med Assoc Thai. 2010;93:S139–44.
Prasad S, Aggarwal BB. Turmeric, the golden spice: from traditional medicine to modern medicine. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton:CRC Press;2011.
Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1–7.
Department of Medical Sciences. Thai herbal pharmacopoeia, vol. I. Bangkok: Prachachon; 2009.
Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem Pharmacol. 2008;76:1590–611.
Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem. 1997;27:S26–34.
Pubchem Compound. Cited on 8 August 2014 by using search term “Curcumin” https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=969516&loc=ec_rcs.
Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16:259–65.
Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486–94.
Zhongfa L, Chiu M, Wang J, Chen W, Yen W, Fan-Havard P, et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol. 2012;69:679–89.
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–18.
Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC/MS/MS. J Chromatogr B. 2007;853:183–9.
Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014;66:222–307.
Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005;7:E118–33.
Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 2010;11:603–17.
Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J Pharm Sci. 2011;100:1987–95.
Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal. 2006;40:720–7.
Zhang W, Tan TM, Lim LY. Impact of curcumin-induced changes in p-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos. 2007;35:110–5.
Liang G, Yang S, Zhou H, Shao L, Huang K, Xiao J, et al. Synthesis, crystal structure and anti-inflammatory properties of curcumin analogues. Eur J Med Chem. 2009;44:915–9.
Rinwa P, Kumar A. Piperine potentiates the protective effects of curcumin against chronic unpredictable stress-induced cognitive impairment and oxidative damage in mice. Brain Res. 2012;1488:38–50.
Steward WP, Gescher AJ. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res. 2008;52:1005–9.
Wichitnithad W, Nimmannit U, Wacharasindhu S, Rojsitthisak P. Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment. Molecules. 2011;16:1888–900.
Wongsrisakul J, Wichitnithad W, Rojsitthisak P, Towiwat P. Antinociceptive effects of CDD in animals models. J Health Res. 2010;24:175–80.
Fan J, Lannoy IAM. Pharmacokinetics. Biochem Pharmacol. 2014;87:93–120.
Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, et al. Curcumin structure–function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J Pharmacol Exp Ther. 2008;326:196–208.
Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacologica et Toxicologica. 1978;43:86–92.
Balant LP, Doelker E, Buri P. Prodrugs for the improvement of drug absorption via different routes of administration. Eur J Drug Metab Pharmacokinet. 1990;15:143–53.
Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–6.
Ajazuddin, Alexander A, Qureshi A, Kumari L, Vaishnav P, Sharma M, et al. Role of herbal bioactives as a potential bioavailability enhancer for active pharmaceutical ingredients. Fitoterapia. 2014;97C:1–14.
Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci. 2000;67:2785–93.
Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomark Prev. 2002;11:105–11.
Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol. 2007;595:269–300.
Parkinson A, Ogilvie BW. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarette and Doull’s toxicology; the basic sciences of poisons. 7th ed. New York: McGraw-Hill; 2007. p. 161–304.
Acknowledgments
The technical language amendment was supervised by Dr. Ian S. Haworth, Dr. Jessica T. Lin and Dr. Delia Bethell.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research was supported by the Ratchadaphiseksomphot Endowment Fund 2013 of Chulalongkorn University, CU-56-329-HR. Dr. Kunan Bangphumi was working under the Postdoctoral Scholarship of Ratchadaphiseksomphot Endowment Fund of Chulalongkorn University.
Conflicts of interest
All authors declare no conflict of interest.
Ethical approval
Animal procedures complied with the guidelines of the Institutional Animal Care and Use Committee of Chulalongkorn University, approval number 13-33-008.
Rights and permissions
About this article
Cite this article
Bangphumi, K., Kittiviriyakul, C., Towiwat, P. et al. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats. Eur J Drug Metab Pharmacokinet 41, 777–785 (2016). https://doi.org/10.1007/s13318-015-0308-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-015-0308-z